Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.
作者信息
Xia Tian, Wang Yanfeng
机构信息
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
出版信息
Am J Transplant. 2020 Sep;20(9):2630-2631. doi: 10.1111/ajt.15992. Epub 2020 Jun 12.
Abstract
摘要
相似文献
1
Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.2019冠状病毒病与移植：洛匹那韦/利托那韦和羟氯喹的联合使用导致他克莫司谷浓度过高及不良预后。
Am J Transplant. 2020 Sep;20(9):2630-2631. doi: 10.1111/ajt.15992. Epub 2020 Jun 12.
2
Two distinct cases with COVID-19 in kidney transplant recipients.两例肾移植受者感染 COVID-19 的病例报告。
Am J Transplant. 2020 Aug;20(8):2269-2275. doi: 10.1111/ajt.15947. Epub 2020 May 16.
3
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).一名2019冠状病毒病（COVID-19）肾移植患者存在危及生命的药物相互作用。
Transpl Infect Dis. 2020 Aug;22(4):e13286. doi: 10.1111/tid.13286. Epub 2020 Jul 14.
4
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.SARS-CoV-2：洛匹那韦/利托那韦、达芦那韦/乌苯美司、羟氯喹、瑞德西韦、法匹拉韦等药物治疗新型冠状病毒的抗病毒治疗的最新报告。
Curr Med Chem. 2020;27(27):4536-4541. doi: 10.2174/0929867327666200416131117.
5
COVID-19 in kidney transplant recipients.肾移植受者中的新型冠状病毒肺炎
Am J Transplant. 2020 Jul;20(7):1941-1943. doi: 10.1111/ajt.15891. Epub 2020 Apr 12.
6
Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain.西班牙安达卢西亚地区针对 2019 年冠状病毒病（COVID-19）治疗的临床方案差异。
Int J Environ Res Public Health. 2020 Sep 19;17(18):6845. doi: 10.3390/ijerph17186845.
7
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
8
COVID-19 in solid organ transplant recipients: A single-center case series from Spain.实体器官移植受者中的 COVID-19：来自西班牙的单中心病例系列。
Am J Transplant. 2020 Jul;20(7):1849-1858. doi: 10.1111/ajt.15929. Epub 2020 May 10.
9
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.新型冠状病毒肺炎治疗中药物组合的安全性评估：基于计算毒理学和基因组学的大数据挖掘方法。
Toxicol Appl Pharmacol. 2020 Nov 1;406:115237. doi: 10.1016/j.taap.2020.115237. Epub 2020 Sep 11.
10
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.洛匹那韦利托那韦治疗的 2 例 COVID-19 患者出现血清素综合征。
J Neurol Sci. 2020 Aug 15;415:116944. doi: 10.1016/j.jns.2020.116944. Epub 2020 May 27.
引用本文的文献
1
Pharmacokinetic Interactions of Paxlovid Involving CYP3A Enzymes and P-gp Transporter: An Overview of Clinical Data.帕罗韦德与CYP3A酶和P-糖蛋白转运体的药代动力学相互作用：临床数据概述
Curr Drug Metab. 2024;25(9):639-652. doi: 10.2174/0113892002320326250123082112.
2
COVID-19: A systematic review and update on prevention, diagnosis, and treatment.新型冠状病毒肺炎：预防、诊断及治疗的系统评价与更新
MedComm (2020). 2022 Feb 17;3(1):e115. doi: 10.1002/mco2.115. eCollection 2022 Mar.
3
COVID-19 in Solid Organ Transplant Recipients: a Review of the Current Literature.实体器官移植受者中的新型冠状病毒肺炎：当前文献综述
Curr Treat Options Infect Dis. 2021;13(3):67-82. doi: 10.1007/s40506-021-00249-6. Epub 2021 Jun 29.
4
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in Kidney transplant patients: A case series and literature review.肾移植患者中的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：病例系列及文献综述
Med J Islam Repub Iran. 2021 Feb 3;35:17. doi: 10.47176/mjiri.35.17. eCollection 2021.
5
COVID-19 in Children With Liver Disease.患有肝脏疾病儿童的新型冠状病毒肺炎
Front Pediatr. 2021 Mar 11;9:616381. doi: 10.3389/fped.2021.616381. eCollection 2021.
6
Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.平息风暴：天然免疫抑制剂作为辅助手段靶向新冠病毒肺炎中的细胞因子风暴
Front Pharmacol. 2021 Jan 27;11:583777. doi: 10.3389/fphar.2020.583777. eCollection 2020.
7
Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study.新型冠状病毒肺炎在肾移植受者中的临床特征：单中心经验和病例对照研究。
Transplant Proc. 2021 May;53(4):1187-1193. doi: 10.1016/j.transproceed.2021.01.002. Epub 2021 Jan 13.
8
COVID-19 in Kidney Transplant Patients From a Large UK Transplant Center: Exploring Risk Factors for Disease Severity.英国大型移植中心的肾移植患者中的 COVID-19：探索疾病严重程度的风险因素。
Transplant Proc. 2021 May;53(4):1160-1168. doi: 10.1016/j.transproceed.2020.11.007. Epub 2020 Dec 17.
9
First Reported Case in Romania of a Successfully Treated Severe COVID-19 in a Kidney Transplant Recipient: A Focus on Acute Kidney Injury.罗马尼亚首例成功治愈的肾移植受者重症新冠肺炎病例报告：聚焦急性肾损伤
Case Rep Nephrol Dial. 2020 Dec 7;10(3):174-179. doi: 10.1159/000512606. eCollection 2020 Sep-Dec.
10
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.新冠病毒患者的转录组特征与药物再利用：生物信息学分析结果
Comput Struct Biotechnol J. 2021;19:1-15. doi: 10.1016/j.csbj.2020.11.056. Epub 2020 Dec 6.
本文引用的文献
1
COVID-19 in solid organ transplant recipients: A single-center case series from Spain.实体器官移植受者中的 COVID-19：来自西班牙的单中心病例系列。
Am J Transplant. 2020 Jul;20(7):1849-1858. doi: 10.1111/ajt.15929. Epub 2020 May 10.
2
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).一名2019冠状病毒病（COVID-19）肾移植患者存在危及生命的药物相互作用。
Transpl Infect Dis. 2020 Aug;22(4):e13286. doi: 10.1111/tid.13286. Epub 2020 Jul 14.
3
Clinical aspects of tacrolimus use in paediatric renal transplant recipients.他克莫司在儿科肾移植受者中的临床应用。
Pediatr Nephrol. 2019 Jan;34(1):31-43. doi: 10.1007/s00467-018-3892-8. Epub 2018 Feb 26.
4
Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.洛匹那韦与利托那韦（克力芝）联用对肝移植患者他克莫司血药浓度的影响。
Liver Transpl. 2003 Sep;9(9):954-60. doi: 10.1053/jlts.2003.50171.
Zotero 插件